Ipsen Sa ADR (OP:IPSEY)

42.01 -0.59 (-1.38%)

Delayed Quote Updated: 1:23 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ipsen Sa ADR

< Previous 1 2 Next >

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure ↗

August 03, 2022

Via Benzinga

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

August 03, 2022

From Ipsen

Via Business Wire

Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic

August 01, 2022

From Ipsen

Via Business Wire

Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance

July 28, 2022

From Ipsen

Via Business Wire

Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission

June 29, 2022

From Ipsen

Via Business Wire

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗

June 27, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.

Via Benzinga

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why ↗

June 27, 2022

Ipsen SA (OTC: IPSEY) has

Via Benzinga

Ipsen to acquire Epizyme, expanding its portfolio in oncology

June 27, 2022

From Epizyme, Inc.

Via Business Wire

Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury

June 09, 2022

From Ipsen

Via Business Wire

Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

May 26, 2022

From Ipsen

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer ↗

May 03, 2022

Via Benzinga

Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

May 03, 2022

From Ipsen

Via Business Wire

Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022

April 27, 2022

From Ipsen

Via Business Wire

EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer ↗

March 25, 2022

Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge ↗

January 24, 2022

Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results...

Via Benzinga

Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease ↗

January 24, 2022

Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans...

Via Benzinga

GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters ↗

December 17, 2021

Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY).

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

December 17, 2021

Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday!

Via InvestorPlace

Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful ↗

December 17, 2021

Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)...

Via Benzinga

Ipsen Stock Declines After Pulling Rare Disease Application ↗

August 13, 2021

Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two...

Via Benzinga

Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders ↗

August 02, 2021

Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as...

Via Benzinga

Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics ↗

July 27, 2021

Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,...

Via Benzinga

Ipsen In-Licenses Parkinson's Candidate From IRLAB ↗

July 15, 2021

Ipsen SA (OTC: IPSEY) and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam. Under the terms of the agreement,...

Via Benzinga

Here's Why Exelixis Stock Is Dropping Today ↗

June 28, 2021

The company reported successful clinical trial results, but investors were still disappointed.

Via The Motley Fool

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

3 Cheap Pharmaceutical Stocks to Grab Now ↗

May 28, 2021

The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.

Via Talk Markets

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.